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Background
Crohn’s disease (CD) is one of the two main forms of 
inflammatory bowel disease (IBD), the other being 
ulcera tive colitis (UC). It is a chronic disease charac­
terized by recurring inflammation of the gut, and is 
thought to arise in response to the commensal 
microflora in a genetically susceptible host [1]. It can 
affect the entire gastrointestinal tract, although the most 
common locations are the terminal ileum and the colon. 
Symptoms can be diffuse, and include (bloody) diarrhea, 
abdominal discomfort, weight loss and anemia, and 
there may also be extra­intestinal symptoms such as 
arthritis, and eye and skin disorders. Complications such 
as strictures often occur in CD, and since the 
inflammation is trans mural, fistulas and abscesses can 
develop, and these eventually require surgical treatment 
[2]. Most of the medications have significant side effects, 
and they are expensive, and often ineffective. CD is a 
major burden on healthcare services, with a prevalence 
of 100 to 150 cases per 100,000 persons per year in the 
western world and with a peak age of onset between 10 
and 30 years of age [3]. CD is partly heritable; this is 
reflected in the higher concordance rate in monozygotic 
twins compared with dizygotic twins. The concordance 
for CD in dizygotic twins is 4%, and for monozygotic 
twins it is as high as 56% [4].
Prior to the introduction of genome­wide association 
studies (GWASs), only a few genetic factors (for example, 
NOD2, which encodes nucleotide binding oligomeriza­
tion domain 2) had unequivocally been associated with 
CD. However, multiple GWASs have now been per­
formed for CD, and a recent meta­analysis carried out by 
Franke et al. [5] has unveiled 71 genetic variants as 
associated with CD; Table 1 highlights some noteworthy 
genes from that study. Many of the genes cluster in 
several different molecular pathways and gene networks. 
In particular, results from GWASs have indicated the 
importance of the immune system in disease patho­
genesis by identifying genes involved in innate and adap­
tive immunity. Hence, the association of IRGM, encoding 
immunity­related GTPase family M, and ATG16L1, 
encoding autophagy­related 16­like 1, with CD has 
implicated the process of autophagy [6]. The association 
of NOD2, CARD9, which encodes caspase recruitment 
domain family member 9, and TLR4, which encodes Toll­
like receptor 4, indicates the involvement of pattern 
recognition mechanisms of the innate immune system 
[7]. Other genes are involved in pro­inflammatory path­
ways (T helper 1 cells and T helper 17 cells) and in anti­
inflammatory pathways (regulatory T cells and IL­10), 
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in dicat ing that adaptive immunity also plays a role in CD 
pathogenesis (Figure 1) [8]. Another interesting association 
mapped to the FUT2 gene, which encodes secretor type 
fucosyltransferase and regulates secretion of A and B 
blood group antigens in intestinal mucosa [9]. Recent 
functional studies have suggested that fucosylation of 
mucin proteins is involved in interception and exclusion 
of bacteria; thus, association of FUT2 with CD might 
imply a role for the functional state of mucin in CD 
patho genesis [10]. Although 5 years of GWASs have 
Table 1. Notable genes within regions associated with Crohn’s disease
Gene	 Odds	ratio	(95%	CI)	 Function
Innate immunity  
	 NOD2 (nucleotide binding oligomerization domain 2) 2.2-4.0 [58] Involved in pattern recognition
	 ATG16L1 (ATG16 autophagy related 16-like 1) 1.34 (1.29-1.40) [5] Involved in autophagy
	 IRGM (immunity-related GTPase family, M) 1.37 (1.28-1.47) [5] Involved in autophagy
	 TLR4 (Toll-like receptor 4) 1.29 (1.08-1.54) [59] Involved in pattern recognition
	 CARD9 (caspase recruitment domain family, member 9) 1.18 (1.13-1.22) [5] Involved in pattern recognition
	 VAMP3 (vesicle-associated membrane protein 3) 1.05 (1.01-1.10) [5] Involved in autophagy and TNF-α metabolism
	 REL (reticuloendotheliosis viral oncogene homolog) 1.14 (1.09-1.19) [5] Transcriptional activator of NF-кB
	 ERAP2 (endoplasmic reticulum aminopeptidase 2) 1.05 (1.02-1.09) [5] Involved in peptide trimming upon NF-кB stimulation; required for 
   the generation of HLA binding peptides
	 UBE2L3 (ubiquitin-conjugating enzyme E2L 3) 0.70 [15] Ubiquitinates, among others, the NF-кB precursor
Adaptive immunity  
	 IL23R	(IL-23 receptor) 2.66 (2.36-3.00) [5] Activates Th17 cells
	 IL12B (IL-12β) 1.18 (1.13-1.24) [5] Stimulates Th0 differentiation to Th1 cells
	 CCR6 (chemokine (C-C motif ) receptor 6) 1.17 (1.12-1.22) [5] Chemoattractant receptor of immune cells
	 HLA-DQA2 (major histocompatibility complex, class II,  1.19 (1.13-1.25) [5] Antigen presenting to Th0
 DQα2)
	 TNFSF11 (tumor necrosis factor super family 11) 1.10 (1.05-1.15) [5] Augments the ability of dendritic cells to stimulate naive T-cell 
   proliferation
	 TNFSF15 (tumor necrosis factor super family 15) 1.21 (1.15-1.27) [5] Mediates activation of NF-кB
	 ICOSLG	(inducible T-cell co-stimulator ligand) 1.18 (1.13-1.23) [5] Acts as a co-stimulatory signal for T-cell proliferation and 
   cytokine secretion
	 IL2RA (IL receptor α) 1.11 (1.05-1.16) [5] Th0 activation
	 TAGAP (T-cell activation GTPase-activating protein) 1.10 (1.05-1.14) [5] May function as a GTPase activating protein and may play 
   important roles during T-cell activation
	 IL10 (IL-10) 1.12 (1.07-1.17) [5] Inhibits synthesis of pro-inflammatory cytokines
	 IL18RAP (IL-18 receptor accessory protein) 1.19 (1.14-1.26) [5] Protein required for NF-кB activation 
	 TYK2	(tyrosine kinase 2) 1.12 (1.06-1.19) [5] Probably involved in intracellular signal transduction by 
   initiation of IFN signaling
	 JAK2 (Janus kinase 2) 1.18 (1.13-1.23) [5] Involved in JAK/STAT pathway; mediates signal transduction 
   of many cytokines
	 STAT3	(signal transducer and activator of transcription 3) 1.15 (1.10-1.21) [5] Involved in JAK/STAT pathway; mediates signal transduction 
   of many cytokines
	 SMAD3	(SMAD family member 3) 1.12 (1.07-1.16) [5] Involved in Treg activation through TGF-β signal transduction
	 ICAM1,3 (intercellular adhesion molecule)  1.12 (1.06-1.19) [5] Homing of leukocytes to inflammation
Other genes of interest  
	 MUC1,19 (mucin)  1.74 (1.55-1.95) [5] Involved in mucus production, to protect the epithelial barrier 
	 FUT2 (fucosyltransferase 2) 1.07 (1.04-1.11) [5] Involved in the A and B antigen synthesis pathway
	 PUS10 (pseudouridylate synthase 10) 1.16 [19] Post-transcriptional nucleotide modification of structural RNAs, 
   including tRNA, rRNA and sRNAs
Genes that we consider to be noteworthy in the Crohn’s disease associated loci. Further investigation is necessary to identify the causal variants. CI, confidence 
interval; HLA, human leukocyte antigen; IFN, interferon; IL, interleukin; JAK, Janus kinase; NF, nuclear factor; rRNA, ribosomal RNA; sRNA, splicing RNA; STAT, signal 
transducer and activator of transcription; TGF, transforming growth factor; Th, T helper cell; TNF, tumor necrosis factor; Treg, regulatory T cell; tRNA transferRNA.
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Figure	1.	See	next	page	for	legend.
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identified a substantial number of CD susceptibility loci, 
as much as 77% of the estimated heritability for CD is still 
considered to be unexplained [5].
Thus, one of the current challenges in the study of CD, 
like other complex diseases, is to identify potential 
sources of this hidden heritability. These might be 
additional common variants with very limited effect size, 
or rare variants with a higher effect size. Part of the 
hidden heritability may lie in structural variations such as 
copy number variations (CNVs; a type of structural DNA 
sequence alteration, including deletions, duplications, 
insertions and inversions, that results in varying numbers 
of copies of a particular gene or DNA sequence from one 
person to the next) or even more complicated mecha­
nisms, such as epistatic, gene­environment and epi­
genetic interactions.
In this review, we discuss the known genetic risk 
factors for CD, the potential sources of the hidden 
heritability, and strategies to investigate these.
Further exploration of GWAS results
Thus far, the GWASs performed for CD have implicated 
many genes, and have thereby provided valuable insights 
into the etiology of CD. However, there are several ways 
to explore GWAS results in more depth that might lead 
to solving a part of the hidden heritability puzzle. The 
design of GWASs holds several limitations, with the first 
being the extensive correction needed for multiple 
testing. Hence, many true­positive findings are discarded 
because of the stringent significance thresholds, and large 
amounts of data are therefore ignored. Several methods 
have been applied successfully to overcome this statistical 
power issue. A major step to overcoming this problem 
has been taken by the International IBD Genetics Con­
sortium (IIBDGC) [11], which performed a novel 
meta­analysis of six index GWASs and a follow­up study 
in independent cohorts. This study increased the number 
of confirmed CD loci to 71, although the explained 
herita bility only increased from 20% to 23% [5].
Another way to overcome the lack of power inherent in 
GWASs is to follow­up specific SNPs (variation in a 
single base in the DNA sequence; the most common type 
of variation in the human genome) identified by them. 
Following up the top 1,000 less­strongly associated loci, 
for example, could yield new true associations. Meta­
analysis of these results with the results from the index 
GWASs leads to a gain of power, as shown by a study of 
celiac disease [12]. Another approach is to prioritize 
genes from the top associated loci based on interaction 
or functional analyses. This has proven to be a successful 
strategy in rheumatoid arthritis, where genes were 
prioritized based on network analysis or interaction 
analysis [13]. For CD, Wang et al. [14] used a different 
prioritizing criterion based on pathway analysis and they 
uncovered a significant association between susceptibility 
to CD and the IL­12/IL­23 pathway, harboring 20 genes. 
Prioritizing SNPs based on their effect on gene expression 
(for example, expression quantitative trait locus, a locus 
at which genetic allelic variation(s) correlates with varia­
tion in gene expression) led to identification of potentially 
novel associations of CD with UBE2L3, encoding ubiquitin­
conjugating enzyme E2L 3 (involved in ubiquitinating the 
NF­кB precursor), and BCL3, encoding B­cell lymphoma 
3­encoded protein (involved in downregulation of the 
NF­кB pathway) [15].
Results of GWASs and their meta­analyses have 
revealed that multiple autoimmune diseases have a 
common genetic architecture [16]. Several studies have 
been successful in identifying new CD risk variants by 
testing previously established loci for other 
Figure	1.	Schematic	representation	of	the	genes	and	pathways	associated	with	Crohn’s	disease	pathogenesis. The ongoing inflammatory 
response in the gastrointestinal tract in patients with Crohn’s disease (CD) is thought to be caused by an aberrant immune response to commensal 
microflora in the gut. In patients with CD, defects in first defense mechanisms (that is, disrupted epithelial and mucosal barrier) contribute to 
increased bacterial penetration (MUC1 and MUC19). Genes involved in pattern recognition (NOD2,	TLR4	and CARD9) suggest an increased response 
of antigen-presenting cells to commensal microbes. Consequently, the NF-кB cascade is activated (TNFSF15), leading to production of pro-
inflammatory cytokines. Association of REL and UBE2L3	suggest an impaired NF-кB negative feedback. Antigen-presenting cells migrate to Peyer’s 
patches (intestinal mesenteric lymph nodes) (TNFSF11) to present antigens and stimulate T-cell proliferation (IL2RA	and TAGAP) and differentiation. 
T cells of patients with CD, in turn, respond more intensely. Th0 cells are stimulated to differentiate into T-cell subtypes regulated by a variety of the 
produced cytokines and their receptors. Th17 cells are involved in many immune-related diseases, and they are activated through IL-23R, which, 
in turn, activates the JAK-STAT-TYK (Janus kinase-signal transducer and activator of transcription-tyrosine kinase) pathway that enhances pro-
inflammatory cytokine production (JAK2,	STAT3 and	TYK2). Th1 and Th17 cells are pro-inflammatory, whereas Treg cells downregulate the immune 
response. Another major contribution to CD pathogenesis comes from autophagy. In autophagosomes, intracellular components, including 
phagocytosed microbes, are degraded, after which their antigens are presented to CD4+ cells. Autophagy is at least partly regulated by the CD risk 
genes ATG16L1, IRGM and VAMP3. The activation of CD4+ cells leads to the production of pro-inflammatory cytokines and the maintenance of the 
inflammation. All the displayed processes could finally lead to homing of leukocytes to inflammation sites (ICAM1,3, CCR	cluster), and neutrophil 
recruitment. Consequently, chronic inflammation, ulceration and deeper microbial penetrance occur. The known associated genes are shown 
in red. Table 1 summarizes the associated loci shown here. CCL20, chemokine (C-C motif ) ligand 20; ICOS, inducible T-cell co-stimulator; MDP, 
muramyl dipeptide; NF, nuclear factor; TCR, T-cell receptor; TGF, transforming growth factor; TGFBR, TGF β receptor; Th, T helper cell; TNF, tumor 
necrosis factor; Treg, regulatory T cell.
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immune­related diseases [17,18]. Festen et al. [19] 
developed a new method to identify shared risk loci of 
two immune­mediated diseases with a partially shared 
genetic back ground, namely celiac disease and CD. To 
increase the statistical power, they performed a 
combined analysis of GWAS results from celiac disease 
and CD, and identified TAGAP, which encodes T­cell 
activation GTPase­activat ing protein, and PUS-10, 
which encodes tRNA pseudo uridylate synthase, as new 
shared loci [19].
The second limitation of the GWAS design is that it 
does not lead to the identification of causal variants, 
since the tested SNPs are merely tagging SNPs in 
linkage dis equilibrium (LD; a non­random association 
of alleles at two or more loci as a result of a recent 
mutation, genetic drift, selection, or non­random 
mating) with the causal variants. Therefore, the effect 
sizes of known CD loci may be an underestimation of 
their actual relative risk. To further investigate the 
known risk loci and identify new SNPs, either as causal 
or close­to­causal variants, exten sive fine­mapping is 
currently being performed by the IIBDGC using a 
custom­made GWA chip. In addition, cross­ethnicity 
fine­mapping has proven successful in exploring 
conserved haplotype structures (that is, LD blocks) [20]. 
The most common LD blocks occur in all populations; 
however, their frequencies vary among different 
ethnicities [20]. For example, common NOD2 and 
IL23R variants that are well established in Caucasians 
could not be replicated in an Indian population, 
implying that additional variants in these or other 
candidate genes may play a role in the pathogenesis of 
CD in Indians [21]. This principle was also successfully 
applied in analyzing the IL2/IL21 LD block, which is 
strongly conserved in Caucasians as opposed to Han 
Chinese, in which the IL2 and IL21 genes reside on two 
distinct LD blocks. Both IL2 and IL21 could be 
identified as separate UC risk loci in Han Chinese [22].
Park et al. [23] proposed a method to evaluate 
statistical power and risk prediction of future GWASs. 
They estimated that there are, in total, 142 CD suscep­
tibility loci with effect sizes similar to the loci reported 
in the current GWASs, and that a sample size of 
approxi mately 50,000 would be needed to uncover 
them. However, even if a GWAS with hundreds of 
thousands of cases were to provide new CD 
susceptibility loci and explain more of the genetic 
variance, it seems unlikely that it would capture even 
half of the estimated herita bility since 142 loci only 
explain 20% of the sibling relative risk for CD. We can 
speculate that identification of the true causal variants 
could amplify the effect size for some of the known loci 
and could consequently increase the discriminatory 
power of risk models.
Another potential source of hidden heritability could 
lie in sample mix­ups that occur accidentally during 
sample collection, genotyping or data management. Some 
genetic variants influence gene expression pheno types 
(expression quantitative trait loci); this allows checking 
for concordance between phenotypic measurements and 
genetic variants that affect these phenotypes. Westra et 
al. (personal communication) found that 3% of sample 
mix­ups decrease the number of loci normally discovered 
by 23% for a trait with a heritability of 50% and 500 loci 
explaining the total heritability. Thus, sample mix­ups 
may explain part of the hidden heritability and it will be 
possible to detect them as long as databases encompass 
sufficient numbers of phenotypes that are strongly 
determined by known genetic variants.
GWASs are most likely to remain an important 
approach for investigating the hidden heritability, since 
the potential of their results can be enhanced by: per­
form ing meta­analyses (for example, between multiple 
GWASs or between similar disease phenotypes); 
following­up prioritized SNPs based on pathway, 
functional or inter action analyses; studying SNPs that 
have been associated with other immune­related 
diseases; and expanding the design of GWASs to include 
samples from non­Caucasians.
Low frequency and rare variants
Common variants identified by GWASs represent only 
a small fraction of the phenotypic variation. Thus, 
much speculation about the hidden heritability has 
focused on the contribution of variants with low allele 
frequencies, defined as 0.5% < minor allele frequency 
(MAF; propor tion of the less common of two alleles in 
a population) <  5%, or from rare variants with MAF 
<0.5%, that are not sufficiently frequent to be captured 
by current GWA arrays, nor sufficiently penetrant to be 
captured by traditional, family­based linkage studies 
[24]. Detecting such variants will be facilitated by 
advances in high­throughput sequencing technologies 
and by the wide­ranging catalog of variants with MAF 
>1% generated by the 1000 Genomes Project [25]. 
Current efforts to identify rare variants by sequencing 
are likely to focus on the regions of most significant 
GWAS SNPs and around genes already implicated in 
CD pathogenesis or treat ment. Resequencing of 
selected susceptibility loci has led recently to the 
discovery of three IL23R (the gene en coding IL­23 
receptor) coding variants that offer protec tion against 
CD [26]. The results of this particular study confirmed 
an increase in effect size with decreasing variant 
frequency, although rare variants explained less of the 
heritability than common variants.
In addition to resequencing efforts, whole­genome/
exome sequencing will be needed to detect rare high­risk 
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variants beyond the LD reach of tag SNPs. Although the 
costs of next­generation sequencing remain high, they 
are dropping fairly rapidly as the technologies improve 
and the process time per sample is becoming shorter; so 
this method is becoming more and more feasible and 
accessible for researchers. Evaluating such signals and 
determining the real causal variant will, however, be a 
difficult task. Feng and Zhu [27] developed an alternative 
method for searching for rare variants in previously 
published GWAS datasets. Their method relies on haplo­
type analysis across the genome and the hypothesis that 
multiple rare variants can be captured by many haplo­
types. Using this method, they confirmed nine previously 
established loci and also discovered four new CD 
susceptibility loci [27].
Another approach that may prove to be important is 
performing resequencing studies of individuals with 
extreme phenotypes in lipid levels; these studies have 
shown that such individuals seem more likely to be the 
carriers of rare, yet non­synonymous, variants [28]. A 
large number of rare variants may have distinct effects on 
the phenotype. Therefore, pooling variants of similar 
effect and locus­specific matching of cases with specific 
CD subphenotypes and controls throughout the genome 
may help to reveal some of the hidden heritability [29].
Structural variation
It has been estimated that chromosomal rearrangements 
(that is, duplications, deletions, insertions and inver­
sions), collectively named CNVs, comprise 12% of the 
human genome [30]. Currently, more than 15,000 CNV 
loci are catalogued in the Database of Genomic Variants 
[31]. Some CNVs have been linked to complex disorders, 
such as autism, neuroblastoma and systematic lupus 
erythematosus [32­34]. A recent study suggested that 
CNVs are enriched in genomic regions containing genes 
that influence immunity [35]. In particular, low and high 
copy numbers of the β­defensin gene (HBD2), which acts 
as an antimicrobial peptide and as a cytokine, have been 
found to predispose to colonic CD [36,37]. Yet, in a 
recent study, Aldhous et al. [38] failed to replicate both 
of the previously published associations. Moreover, they 
argued that these two associations could be due to 
measure ment error because of a general deficiency of 
real­time PCR to distinguish multiple CNV clusters. In 
addition to the β­defensins, a fine­mapping study of the 
IRGM susceptibility locus revealed a 20­kb deletion 
polymorphism immediately upstream of IRGM that was 
associated with CD risk and IRGM expression [39]. 
Further more, a recent GWAS of CNVs from the 
Wellcome Trust Case Control Consortium has 
confirmed these CNVs for CD, and also discovered new 
CNVs in the IRGM and human leukocyte antigen (5.1 
kb) regions [40]. The Wellcome Trust Case Control 
Consortium study also showed that the most common 
CNVs are well tagged by SNPs in current GWAS chips, 
and that they are unlikely to make much contribution to 
the hidden heritability in common diseases. More work 
is needed to elucidate the functional consequences and 
impact of high copy­number repeats (for example, long 
interspersed nuclear elements), and of rare CNVs on 
clinical phenotypes, such as CD.
Family-based approaches
Since the possibility of chip­based GWASs became 
available, linkage analysis and family­based approaches 
have been largely discarded. However, now that the 
opportunities for gene detection by conventional GWASs 
have been almost exhausted, researchers are shifting back 
towards family­based approaches. These approaches can 
be helpful when GWASs fail to detect signals from rare 
variants and are biased by population stratification, 
which is defined as a presence of subpopulations in a 
supposedly homogeneous population. Subpopulations 
arise from differences in allele frequencies between 
individuals as a consequence of distinct ancestral and/or 
demographic origin. Family­based studies may also be 
advantageous since the low frequency risk alleles (SNPs 
with MAF <5%) are likely to be more prevalent in large 
families with several affected members and should 
therefore be easier to detect. By assessing GWAS data in 
such families, large regions of identity­by­descent may be 
identified and found to include genes associated with CD; 
this approach has already proved to be a powerful tool in 
classical linkage analysis. However, the shared environ­
ment of family members is an alternative explanation for 
familial clustering that should be taken into account. 
Glocker et al. [41] identified loss­of­function mutations 
in two loci by considering early onset colitis as a mono­
genic trait in two consanguineous families. They per­
formed a genetic linkage analysis followed by candidate 
gene sequencing and identified the IL10RA (the gene 
encoding IL­10 receptor α) and IL10RB (the gene 
encoding IL­10 receptor β) loci as being associated with 
early­onset enterocolitis. However, it is most likely that in 
this particular case a private variant, not present in the 
general population, is responsible for the disease.
Akolkar et al. [42] found that CD is subject to a 
parent­of­origin effect, indicating that loci affected 
by genomic imprinting play a role in CD pathogenesis. 
In genomic imprinting, the expression of an inherited 
variant is deter mined by the parent from whom that 
variant is inherited. If the maternal allele, for 
instance, is inacti vated by genomic imprinting, then 
expression of the locus is determined by the paternal 
allele only. If this effect is not taken into account, a 
significant loss in the statistical power of the study 
might develop [43].
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Family­based approaches may be useful in the search 
for the hidden heritability since low­frequency variants 
accumulate in families with multiple affected 
individuals; moreover, low­frequency variants are not 
affected by popu lation stratification and they also 
include parent­of­origin effects. However, the causal 
variants identified in such families may prove to be 
private variants or the shared environment may play a 
major role.
GWAS aftermath: epistatic, gene-environment and 
epigenetic interactions
Given that a large proportion of the heritability of CD 
and its complex architecture is as yet unexplained, one 
might speculate other aspects of inheritance, such as 
epistasis, gene­environment interactions or epigenetic 
effects, might be involved. GWASs may be missing 
higher­order genetic effects that arise from the inter­
action of two or more SNPs [44]. The underlying idea 
for such epistatic effects is that a significant proportion 
of the hidden heritability is not due to single common 
variants, nor to single rare variants, but rather to rare 
combinations of common variants. Since typical 
GWASs examine the association of single SNPs with a 
phenotype, SNPs that contribute epistatically will not 
be revealed by such an analysis. A recent pair­wise 
analysis of variants related to the IL17-IL23 pathway 
showed an increasing odds ratio for CD when the ‘risk’ 
haplotypes for these genes were combined [45]. 
Analysis of epistatic inter actions in better­powered 
datasets, and the use of more efficient computational 
approaches that can account for the complex nature of 
biomolecular networks, may yield new genetic risk 
factors for CD [46,47].
An even more complex source for the hidden herita­
bility might lie in gene­environment interactions, which 
are defined as the joint effect of one or more genes with 
one or more environmental factors that cannot be readily 
explained by their separate marginal effects [48]. The 
strongest and best replicated environmental risk factor 
for CD is smoking, which increases both the risk and 
severity of CD. However, a recent, moderately sized study 
found remarkable differences in associated loci between 
smoking and non­smoking CD patients, thereby implying 
that a complex gene­environment interaction must be at 
work [49]. Another example of the complex interaction 
between genetic and environmental factors was shown in 
a study by Cadwell et al. [50] where Atg16L1-deficient 
mice infected with a specific strain of norovirus developed 
CD­like phenotypes in a model of intestinal injury 
induced by dextran sodium sulfate. In particular, struc­
tural Paneth cell abnormalities and decreased production 
of antimicrobial granules in the mice resembled those 
found in CD patients who are homozygous carriers of the 
ATG16L1 risk alleles. Remarkably, the severity of intes­
tinal injury induced by dextran sodium sulfate was not 
only dependent on aberrant Atg16L1 function and 
norovirus infection, but also on the timing of infection, 
secretion of the pro­inflammatory cytokines TNF­α and 
IFN­γ, and the presence of commensal bacteria in the 
mouse intestine.
Other environmental factors, such as appendectomy, 
diet and domestic hygiene habits, may also play a role in 
CD, but the evidence for each of these factors is much 
weaker. To study gene­environment interactions will 
require careful consideration of the epidemiologic study 
design, exposure assessment, and methods of analysis, 
paying particular attention to ways of harmonizing these 
features across consortia.
An additional source of the hidden heritability might 
not lie in the genome sequence itself, but in subtle 
mechanisms interfering with genome functions, such as 
gene expression. These mechanisms include histone 
modification, methylation and gene inactivation, and 
are covered by the study of epigenetics. However, there 
is much controversy on this topic. Its role in CD is un­
known, but there are some hints that methylation plays 
a role in other complex diseases: type 2 diabetes, 
rheuma toid arthritis and neurodegenerative diseases 
[51­53]. Epigenetics is also correlated with age, gender 
and nutri tion, and it is likely that there are other 
environmental factors to be discovered [54,55]. It has 
been shown that changes in DNA methylation in mice 
can be provoked by dietary alterations and subsequently 
transmitted across generations [56]. Thus, sequence­
independent epigenetic effects (beyond imprinting) that 
might be environ men tally induced and transmitted 
across several generations [57] could represent a 
revolutionary glimpse into the enigmatic world of the 
heritability of complex diseases.
Conclusions
CD is a complex genetic disorder with an estimated 
heritability of 50% and it is characterized by a recurring 
inflammation of the gastrointestinal tract. Two decades 
of research have led to the discovery of 71 risk loci, which 
have improved our understanding of the disease patho­
genesis. At the moment, approximately 23% of the herita­
bility can be explained. To fully understand the disease 
pathogenesis and link current insights to clinically 
relevant knowledge, it is important to continue our quest 
to identify more genetic risk factors in CD. In this review, 
we have presented various potential sources for the 
hidden heritability of complex diseases given the current 
knowledge on CD.
It is unlikely that conventional GWASs alone can solve 
the puzzle of the hidden heritability. They are not power­
ful enough to detect signals from common variants with 
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low impact, nor extensive enough to capture rarer 
variants with high impact. The resources of GWASs are 
expected to be exhausted fairly soon, although new loci 
have recently been identified by replicating prioritized 
SNPs and meta­analysis of GWAS results.
Identification of causal variants may elucidate a sub­
stantial part of the hidden heritability; however, current 
GWASs are insufficient for the purpose of identifying 
causal variants since the identified SNPs are merely the 
surrogates for causal variants. However, fine­mapping 
can uncover SNPs closer to the causal variants, since 
SNPs can then be tested beyond the scope of GWASs. 
The true causal variants might be identified by whole 
genome sequencing or exome sequencing. More sources 
than the linear DNA sequence have to be investigated to 
unravel the total heritability. Epigenetics and gene­
environment studies have been shown to be worthwhile, 
but the study of epistatic effects in CD is still needed, 
and results from other complex genetic diseases seem to 
be promising.
To fully unravel the hidden heritability of CD, colla­
bora tions between genome research centers are crucial, 
since the solutions to identify the hidden heritability are 
either costly or require a huge number of cases and 
controls. The IIBDGC is a good example of what can be 
achieved by performing large meta­analyses, and it is 
currently performing dense fine­mapping and 
replication studies to identify causal variants and 
additional risk loci in CD.
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